222 related articles for article (PubMed ID: 27572815)
21. Paraneoplastic tumefactive demyelination in a 47-year-old man with underlying seminoma.
Van Haver AS; Debruyne F; Sanders K; Verstappen A
Mult Scler Relat Disord; 2020 Jul; 42():102060. PubMed ID: 32217464
[TBL] [Abstract][Full Text] [Related]
22. [Pseudotumors of the central nervous system].
Zámečník J; Mrázková L
Cesk Patol; 2012 Oct; 48(4):184-9. PubMed ID: 23121027
[TBL] [Abstract][Full Text] [Related]
23. Early relapse risk after a first CNS inflammatory demyelination episode: examining international consensus definitions.
Dale RC; Pillai SC
Dev Med Child Neurol; 2007 Dec; 49(12):887-93. PubMed ID: 18039234
[TBL] [Abstract][Full Text] [Related]
24. Characterisation of the spectrum of demyelinating disease in Western Australia.
Wu JS; Zhang MN; Carroll WM; Kermode AG
J Neurol Neurosurg Psychiatry; 2008 Sep; 79(9):1022-6. PubMed ID: 18356258
[TBL] [Abstract][Full Text] [Related]
25. [Pathology, diagnosis, and treatment of combined central and peripheral demyelination].
Matsuse D; Ogata H; Kira J
Nihon Rinsho; 2015 Sep; 73 Suppl 7():352-6. PubMed ID: 26480725
[No Abstract] [Full Text] [Related]
26. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review.
Karussis D
J Autoimmun; 2014; 48-49():134-42. PubMed ID: 24524923
[TBL] [Abstract][Full Text] [Related]
27. Population-based incidence and clinico-radiological characteristics of tumefactive demyelination in Olmsted County, Minnesota, United States.
Fereidan-Esfahani M; Decker PA; Eckel Passow JE; Lucchinetti CF; Flanagan EP; Tobin WO
Eur J Neurol; 2022 Mar; 29(3):782-789. PubMed ID: 34773343
[TBL] [Abstract][Full Text] [Related]
28. A long-term follow-up study using IPMSSG criteria in children with CNS demyelination.
Peche SS; Alshekhlee A; Kelly J; Lenox J; Mar S
Pediatr Neurol; 2013 Nov; 49(5):329-34. PubMed ID: 23993834
[TBL] [Abstract][Full Text] [Related]
29. Nationwide Incidence of Acquired Central Nervous System Demyelination in Icelandic Children.
Gudbjornsson BT; Haraldsson Á; Einarsdóttir H; Thorarensen Ó
Pediatr Neurol; 2015 Dec; 53(6):503-7. PubMed ID: 26463471
[TBL] [Abstract][Full Text] [Related]
30. Pediatric tumefactive multiple sclerosis case (with baló-like lesions), diagnostic and treatment challenges.
Kamari C; Galanakis E; Raissaki M; Briassoulis G; Vlachaki G; Vorgia P
Neurol Sci; 2023 Jan; 44(1):343-345. PubMed ID: 36171523
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors of tumefactive demyelinating lesions and differential features for multiple sclerosis in etiology.
Saridas F; Mesut G; Ceylan CY; Ozpar R; Ozsen M; Koc ER; Tolunay S; Hakyemez B; Turan OF
Mult Scler Relat Disord; 2024 May; 85():105537. PubMed ID: 38460252
[TBL] [Abstract][Full Text] [Related]
32. Acute tumefactive demyelinating lesions in a pediatric patient with known diagnosis of multiple sclerosis: review of the literature and treatment proposal.
Dastgir J; DiMario FJ
J Child Neurol; 2009 Apr; 24(4):431-7. PubMed ID: 19189932
[TBL] [Abstract][Full Text] [Related]
33. Tumefactive demyelinating lesions as a first clinical event: Clinical, imaging, and follow-up observations.
Jeong IH; Kim SH; Hyun JW; Joung A; Cho HJ; Kim HJ
J Neurol Sci; 2015 Nov; 358(1-2):118-24. PubMed ID: 26333950
[TBL] [Abstract][Full Text] [Related]
34. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes.
Cantó E; Tintoré M; Villar LM; Costa C; Nurtdinov R; Álvarez-Cermeño JC; Arrambide G; Reverter F; Deisenhammer F; Hegen H; Khademi M; Olsson T; Tumani H; Rodríguez-Martín E; Piehl F; Bartos A; Zimova D; Kotoucova J; Kuhle J; Kappos L; García-Merino JA; Sánchez AJ; Saiz A; Blanco Y; Hintzen R; Jafari N; Brassat D; Lauda F; Roesler R; Rejdak K; Papuc E; de Andrés C; Rauch S; Khalil M; Enzinger C; Galimberti D; Scarpini E; Teunissen C; Sánchez A; Rovira A; Montalban X; Comabella M
Brain; 2015 Apr; 138(Pt 4):918-31. PubMed ID: 25688078
[TBL] [Abstract][Full Text] [Related]
35. Tumefactive demyelinating lesions: Characteristics of individual lesions, individual patients, or a unique disease entity?
Weinshenker BG
Mult Scler; 2015 Nov; 21(13):1746-7. PubMed ID: 26362899
[TBL] [Abstract][Full Text] [Related]
36. Occurrence and long-term outcome of tumefactive demyelinating lesions in multiple sclerosis.
Totaro R; Di Carmine C; Splendiani A; Torlone S; Patriarca L; Carrocci C; Sciamanna S; Marini C; Carolei A
Neurol Sci; 2016 Jul; 37(7):1113-7. PubMed ID: 27083895
[TBL] [Abstract][Full Text] [Related]
37. [Demyelinating disease affecting both central and peripheral nervous system].
Carra-Dallière C; Mania A; Carlander B; Camu W; Juntas-Morales R
Rev Neurol (Paris); 2011 Dec; 167(12):921-5. PubMed ID: 21596409
[TBL] [Abstract][Full Text] [Related]
38. Clinical and radiological characteristics and outcomes of patients with recurrent or relapsing tumefactive demyelination.
Pervin I; Ramanathan S; Cappelen-Smith C; Vucic S; Reddel SW; Hardy TA
Mult Scler Relat Disord; 2024 Feb; 82():105408. PubMed ID: 38219394
[TBL] [Abstract][Full Text] [Related]
39. Tumefactive demyelinating lesion: experience with two unusual patients.
Sinha MK; Garg RK; Bhatt ML; Chandra A
J Postgrad Med; 2010; 56(2):146-9. PubMed ID: 20622396
[TBL] [Abstract][Full Text] [Related]
40. Tumefactive demyelinating lesions (TDLs): A case series of clinicoradiological features.
Jain RS; Khan I; Kandelwal K; Desai T
Clin Neurol Neurosurg; 2017 Nov; 162():91-94. PubMed ID: 28987645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
